NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: HIKAL · data 2026-11-01
Hikal Limited
In plain words
Price: 18.9% below its 52-week high of ₹261.
Delivery: 38.4% of traded shares were kept for delivery over the last 10 sessions, against 38.6% over the last 60.
Latest results: a net loss of ₹7 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,735 cr |
| Net profit (last 12 months) | ₹-34 cr |
| Sales growth, 3 years (yearly) | -5.4% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 68.8% (unchanged in a year), pledged 0.0%, institutions 6.6%.
ROE -4.0%, ROCE 3.1%, operating margin 3.8%: how much profit it earns on the money it uses.
Debt/equity 0.57, Profit growth — and sales growth -5.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-4.0%).
- Thin operating margin (3.8%).
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
HIKAL Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹402.8 crore, up 5.9% YoY and down 22.4% QoQ.
Net loss was ₹7.4 crore, a smaller loss than a year ago and a turn to loss from a profit last quarter.
Operating margin was 9.2% (6.6% a year ago).
EPS was -₹0.6, less negative than a year ago and negative against a positive EPS last quarter.
HIKAL के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹402.8 करोड़; पिछले साल की तुलना में 5.9% की बढ़त, पिछली तिमाही की तुलना में 22.4% की गिरावट।
शुद्ध घाटा: ₹7.4 करोड़; एक साल पहले से घाटा कम हुआ, पिछली तिमाही के मुनाफ़े से घाटे में आया।
ऑपरेटिंग मार्जिन: 9.2% (एक साल पहले 6.6%)।
EPS: -₹0.6; एक साल पहले से कम ऋणात्मक, पिछली तिमाही के धनात्मक EPS से ऋणात्मक हुआ।
HIKALના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹402.8 કરોડ; ગયા વર્ષની સરખામણીએ 5.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 22.4% ઘટાડો.
ચોખ્ખી ખોટ: ₹7.4 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ ઘટી, ગયા ક્વાર્ટરની સરખામણીએ નફામાંથી ખોટમાં આવી.
ઓપરેટિંગ માર્જિન: 9.2% (એક વર્ષ પહેલાં 6.6%).
EPS: -₹0.6; એક વર્ષ પહેલાંના કરતાં ઓછી નકારાત્મક, ગયા ક્વાર્ટરના હકારાત્મક EPSથી નકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 29.0% over the last 20 sessions vs 15.7% in the 40 before (1.85x); shares delivered per day 0.46x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 7/20: Net +₹1.56 cr bought in bulk/block deals over 90 days (0.14x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend ● Results
- 7 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED bought ₹1.56 cr +10.7% next session
- 4 Sept 26Dividend Dividend ₹0.4 (ex-date) +1.1% next session
- 6 Aug 26Results Q1 FY27 results: loss narrowed vs a year ago -2.3% next session
- 27 May 26Results Q4 FY26 results: profit −71.3% YoY -10.4% next session
- 17 Feb 26Dividend Dividend ₹0.2 (ex-date) -1.8% next session
- 11 Feb 26Results Q3 FY26 results: turned to loss vs a year ago +13.6% next session
- 13 Jan 26Results Q2 FY26 results: turned to loss vs a year ago -1.4% next session
- 2 Sept 25Dividend Dividend ₹0.8 (ex-date) +4.5% next session
- 7 Aug 25Results Q1 FY26 results: turned to loss vs a year ago -5.5% next session
- 14 May 25Results Q4 FY25 results: profit +47.8% YoY -3.7% next session
- 7 Feb 25Dividend Dividend ₹0.6 (ex-date) -6.8% next session
- 5 Feb 25Results Q3 FY25 results: profit +6.6% YoY +8.8% next session
- 12 Nov 24Results Q2 FY25 results: profit +45.6% YoY +2.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹403 cr | ₹-7 cr | — | 9.2% | -0.6 |
| Mar 2026 | ₹519 cr | ₹14 cr | -71.3% | 20.3% | 1.17 |
| Dec 2025 | ₹494 cr | ₹-6 cr | -134.3% | 16.7% | -0.48 |
| Sept 2025 | ₹319 cr | ₹-35 cr | -290.7% | 2.3% | -2.83 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 68.85% | 68.85% | 68.85% | 68.85% |
| Foreign institutions (FII) | 1.27% | 0.99% | 1.43% | 2.30% |
| Domestic institutions (DII) | 5.32% | 7.24% | 7.20% | 7.05% |
| Mutual funds | 5.09% | 5.92% | 5.92% | 5.71% |
| Retail investors | 16.71% | 15.97% | 15.37% | 14.79% |
| Number of shareholders | 74,784 | 73,527 | 74,270 | 74,117 |
Common questions
What was Hikal Limited's latest quarterly profit?
Hikal Limited reported a net loss of ₹7 cr for the quarter ended Jun 2026, on revenue of ₹403 cr.
How much do promoters hold in Hikal Limited?
Promoters held 68.85% of Hikal Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Hikal Limited debt-free?
Its latest reported debt-to-equity ratio is 0.57.
What is the 52-week high and low of Hikal Limited?
The 52-week high is ₹261 and the 52-week low is ₹146.25.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Hikal Limited | ₹211.58 | ₹2,601 cr | — | — | -4% | 3.1% | 0.57 | -13.1% |
| Solara Active Pharma Sciences Ltd. | ₹632.6 | ₹3,043 cr | 84.2 | 2.1 | -0.6% | 5.9% | 0.55 | +6.1% |
| Sai Parenterals Limited | ₹521.95 | ₹2,302 cr | — | — | 4.9% | 5.8% | 0.96 | +30.5% |
| Dishman Carbogen Amcis Ltd. | ₹145.02 | ₹2,276 cr | 33.3 | — | 1.6% | 2.6% | 0.46 | -50.5% |
| Fredun Pharmaceuticals Ltd. | ₹1,367 | ₹2,259 cr | 49.7 | — | 15.6% | 33% | 0.87 | -11.2% |
| Alembic Limited | ₹87.22 | ₹2,239 cr | 7 | — | 13.3% | 3.3% | 0 | -13.2% |
Compare HIKAL with SOLARA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HIKAL in NSE Scanner →